多西他赛联合希罗达治疗蒽环类耐药转移性乳腺癌临床观察

Clinical Observation of Combined Use of Docetaxel and Xeloda in Anthracyclines Resistant Advanced Breast Cancer

目的：观察及评价多西他赛联合希罗达治疗蒽环类耐药性乳腺癌的疗效和不良反应。方法：32例经病理证实的蒽环类耐药性乳腺癌患者均给予多西他赛75mg/m2,第1天;希罗达1250mg/m2,餐后口服,2次/d,连续服用14d,治疗周期为21d,至少治疗2个周期。结果：本组32例患者中完全缓解（CR）4例,部分缓解（PR）12例,稳定（SD）9例,疾病进展（PD）7例。总有效率为50.0%,肿瘤控制率为78.1%,中位疾病进展时间（TTP）5.5个月。主要不良反应为骨髓抑制,其中Ⅲ~Ⅳ级白细胞减少占25.0%,其次为手足综合征、恶心、呕吐等不良反应,对症处理均可耐受。结论：多西他赛联合希罗达是治疗蒽环类耐药复发转移性乳腺癌的较好方案。

Objective:To observe the curative effect and toxicity of Docetaxel plus Xeloda in breast cancer patients who were drug resistance to anthracene nucleus drugs. Methods:32 patient received docetaxel 75mg/m2 on d1 and xeloda 1250mg/m2 on d1~d14 of every 21 days. Every patient was administered no less than 2 cycles. Results:in all patients, there were 4 cases whose curative effects reached CR,12 cases whose curative effects reached PR,9 cases whose curative effects reached SD,7 cases whose curative effects reached PD. The total responsive rate was 50.0%, the clinical disease control rate was 78.1%, the median survival time was 5.5 months. The main toxic reactions were myelosuppression, grade 3 and 4 adverse events including leuopenia was 25.0% .Most common grade 1 and 2 adverse events were hand-foot syndrome, nausea and vomiting and diarrbea and the toxic reactions was tolerable. Conclusion:The combined Use of Docetaxel and Xeloda can exert a better control of the anthracyclines resistant metastatic breast cancer.